Float Short %

10.26

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

EPS Last/This Y

-0.43

EPS This/Next Y

0.2

Price

2.35

Target Price

7.75

Analyst Recom

1.44

Performance Q

101.72

Relative Volume

1.9

Beta

1.94

Ticker: GOSS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	GOSS	1.985	0.04	0.00	58958
2025-07-29	GOSS	1.96	0.04	0.00	59059
2025-07-30	GOSS	2.07	0.03	0.00	70691
2025-07-31	GOSS	2.04	0.03	0.00	69895
2025-08-01	GOSS	2	0.03	0.00	69675
2025-08-04	GOSS	2.16	0.03	0.02	72129
2025-08-05	GOSS	2.15	0.03	0.01	72424
2025-08-06	GOSS	1.98	0.03	0.01	82718
2025-08-07	GOSS	1.72	0.03	0.13	83461
2025-08-08	GOSS	1.765	0.03	0.01	83402
2025-08-11	GOSS	1.735	0.03	0.02	83658
2025-08-12	GOSS	1.925	0.03	0.00	83901
2025-08-13	GOSS	1.98	0.03	0.04	83980
2025-08-14	GOSS	1.955	0.03	0.04	84073
2025-08-15	GOSS	1.965	0.03	0.00	84193
2025-08-18	GOSS	1.995	0.03	0.00	76175
2025-08-19	GOSS	1.925	0.03	0.64	76070
2025-08-20	GOSS	1.945	0.03	0.18	76097
2025-08-21	GOSS	2.165	0.03	0.29	76184
2025-08-22	GOSS	2.345	0.04	0.00	76556
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	GOSS	1.99	-183.8	-108.3	-0.69
2025-07-29	GOSS	1.96	-183.6	-94.2	-0.69
2025-07-30	GOSS	2.08	-183.6	-105.0	-0.69
2025-07-31	GOSS	2.04	-183.6	-92.5	-0.69
2025-08-01	GOSS	2.00	-183.6	-92.5	-0.69
2025-08-04	GOSS	2.17	-183.6	-109.0	-0.69
2025-08-05	GOSS	2.16	-183.6	-94.9	-0.69
2025-08-06	GOSS	1.97	-183.6	-82.1	-0.69
2025-08-07	GOSS	1.74	-183.6	13.1	-0.69
2025-08-08	GOSS	1.76	-183.6	-6.4	-0.69
2025-08-11	GOSS	1.74	-39.3	-2.0	-0.73
2025-08-12	GOSS	1.92	-39.3	-18.2	-0.73
2025-08-13	GOSS	1.97	-39.3	-6.2	-0.73
2025-08-14	GOSS	1.96	-39.3	-4.3	-0.73
2025-08-15	GOSS	1.97	-39.3	-6.2	-0.68
2025-08-18	GOSS	2.00	-35.7	-8.3	-0.68
2025-08-19	GOSS	1.92	-35.7	-0.6	-0.68
2025-08-20	GOSS	1.94	-35.7	-6.9	-0.68
2025-08-21	GOSS	2.16	-35.7	-20.6	-0.68
2025-08-22	GOSS	2.35	-35.7	-16.8	-0.68
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	GOSS	0.00	7.03	9.92
2025-07-29	GOSS	0.00	7.03	9.92
2025-07-30	GOSS	0.00	7.03	9.92
2025-07-31	GOSS	0.00	7.03	9.92
2025-08-01	GOSS	0.00	7.03	9.92
2025-08-04	GOSS	0.00	6.31	9.92
2025-08-05	GOSS	0.00	6.31	9.92
2025-08-06	GOSS	0.00	6.31	9.92
2025-08-07	GOSS	0.00	6.31	9.92
2025-08-08	GOSS	0.00	6.31	9.92
2025-08-11	GOSS	0.00	7.31	9.92
2025-08-12	GOSS	0.00	7.31	10.26
2025-08-13	GOSS	0.00	7.31	10.26
2025-08-14	GOSS	0.00	7.31	10.26
2025-08-15	GOSS	0.00	7.31	10.26
2025-08-18	GOSS	0.00	8.81	10.26
2025-08-19	GOSS	0.00	8.81	10.26
2025-08-20	GOSS	0.06	8.81	10.26
2025-08-21	GOSS	0.06	8.81	10.26
2025-08-22	GOSS	0.06	8.81	10.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

0.06

Institutional Transactions

8.81

Beta

1.94

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

84.6

Max Drawdown 5-Year %

-96.8

Target Price

7.75

P/E

Forward P/E

PEG

P/S

13.22

P/B

P/Free Cash Flow

EPS

-0.61

Average EPS Est. Cur. Y

-0.68

EPS Next Y. (Est.)

-0.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-344.81

Relative Volume

1.9

Return on Equity vs Sector %

276.2

Return on Equity vs Industry %

289.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-16.8

Gossamer Bio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 144

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today

news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance

stock history GOSS – Gossamer Bio, Inc. invest stock market

stock prices GOSS premarket after hours

ticker GOSS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GOSS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y